Stem Cell Therapeutics completes $33 million private placement

1 minute read
13 December 2013

On December 13, 2013, Stem Cell Therapeutics Corp. (TSXV: SSS) (OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell-related therapeutics, announced that it had raised gross proceeds of $33 million through a private placement of units.

The financing was led by a prominent U.S. healthcare fund, with participation from several other premier U.S. healthcare institutional investors, including Special Situations Funds, Ridgeback Capital, Merlin Nexus, Sabby Capital, venBio, Opaleye Management and HSMR Advisors. Bloom Burton & Co. acted as lead agent for the private placement. ROTH Capital Partners, LLC acted as placement agent in the United States.

Gowlings advised the agents in this transaction with a team led by Vanessa Grant and that included Steven Cutler and Matthew Literovich (corporate/securities), Anita Nador (intellectual property) and Gloria Geddes (tax), assisted by student-at-law Raj Grewal.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.